GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (LTS:0L49) » Definitions » Net Margin %

SCYNEXIS (LTS:0L49) Net Margin % : 29.93% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is SCYNEXIS Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. SCYNEXIS's Net Income for the three months ended in Mar. 2024 was $0.4 Mil. SCYNEXIS's Revenue for the three months ended in Mar. 2024 was $1.4 Mil. Therefore, SCYNEXIS's net margin for the quarter that ended in Mar. 2024 was 29.93%.

The historical rank and industry rank for SCYNEXIS's Net Margin % or its related term are showing as below:

LTS:0L49' s Net Margin % Range Over the Past 10 Years
Min: -44388.43   Med: -4851.36   Max: 47.84
Current: 47.84


LTS:0L49's Net Margin % is ranked better than
98.53% of 1019 companies
in the Drug Manufacturers industry
Industry Median: 3.25 vs LTS:0L49: 47.84

SCYNEXIS Net Margin % Historical Data

The historical data trend for SCYNEXIS's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS Net Margin % Chart

SCYNEXIS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -44,388.43 - -249.68 -1,233.73 47.84

SCYNEXIS Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,997.88 93.01 -99.77 -337.86 29.93

Competitive Comparison of SCYNEXIS's Net Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SCYNEXIS's Net Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Net Margin % distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's Net Margin % falls into.



SCYNEXIS Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

SCYNEXIS's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=67.041/140.141
=47.84 %

SCYNEXIS's Net Margin for the quarter that ended in Mar. 2024 is calculated as

Net Margin=Net Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=0.411/1.373
=29.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SCYNEXIS  (LTS:0L49) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


SCYNEXIS Net Margin % Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


SCYNEXIS (LTS:0L49) Business Description

Traded in Other Exchanges
Address
1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

SCYNEXIS (LTS:0L49) Headlines

No Headlines